Literature DB >> 12629241

Interobserver variability in the radiological assessment of response to chemotherapy in glioma.

M J Vos1, B M J Uitdehaag, F Barkhof, J J Heimans, H C Baayen, W Boogerd, J A Castelijns, P H M Elkhuizen, T J Postma.   

Abstract

OBJECTIVE: To assess the interobserver variability in the radiologic assessment of response to chemotherapy in patients with recurrent glioma.
METHODS: Five clinicians with experience in the treatment and follow-up of patients with glioma measured tumor size in 20 pairs of CT and 20 pairs of MRI scans of 35 patients who had been treated with chemotherapy for recurrent glioma. Tumor size was defined as the product of the two largest perpendicular enhancing tumor diameters on the postcontrast images. To assess the interobserver variability in the measurements of tumor size, and in the classification according to the widely used Macdonald response criteria, intraclass correlation coefficients (ICC) and weighted kappa values were calculated.
RESULTS: Substantial interobserver agreement was noted in the manual, two-dimensional measurements of tumor size on CT and MRI in patients treated with chemotherapy for recurrent glioma (overall ICC 0.64). Classification of response to chemotherapy according to the Macdonald criteria resulted in moderate interobserver agreement (overall weighted kappa 0.51). In 65% of evaluated CT and in 55% of evaluated MRI studies, no complete consensus was found for the categorical tumor response measurement.
CONCLUSION: The radiologic assessment of response to chemotherapy in patients with recurrent glioma is susceptible to considerable interobserver variability. This underlines the difficulties that arise in scoring response to chemotherapy by conventional radiologic techniques.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629241     DOI: 10.1212/01.wnl.0000049467.54667.92

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Assessment of intra-observer variability in measurement of high-grade brain tumors.

Authors:  James M Provenzale; Michael C Mancini
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Can we improve accuracy and reliability of MRI interpretation in children with optic pathway glioma? Proposal for a reproducible imaging classification.

Authors:  Julien Lambron; Josué Rakotonjanahary; Didier Loisel; Eric Frampas; Emilie De Carli; Matthieu Delion; Xavier Rialland; Frédérique Toulgoat
Journal:  Neuroradiology       Date:  2015-10-30       Impact factor: 2.804

Review 3.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

4.  MRI and thallium-201 SPECT in the prediction of survival in glioma.

Authors:  Maaike J Vos; Johannes Berkhof; Otto S Hoekstra; Ingeborg Bosma; Eefje M Sizoo; Jan J Heimans; Jaap C Reijneveld; Esther Sanchez; Frank J Lagerwaard; Jan Buter; David P Noske; Tjeerd J Postma
Journal:  Neuroradiology       Date:  2011-07-14       Impact factor: 2.804

5.  Synchronized brain activity and neurocognitive function in patients with low-grade glioma: a magnetoencephalography study.

Authors:  Ingeborg Bosma; Linda Douw; Fabrice Bartolomei; Jan J Heimans; Bob W van Dijk; Tjeerd J Postma; Cornelis J Stam; Jaap C Reijneveld; Martin Klein
Journal:  Neuro Oncol       Date:  2008-07-23       Impact factor: 12.300

6.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Authors:  Patrick Y Wen; Timothy F Cloughesy; Benjamin M Ellingson; David A Reardon; Howard A Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M Chang; Michael D Prados; Whitney B Pope; Alma Gregory Sorensen; Martin van den Bent; Wai-Kwan Alfred Yung
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

7.  Emerging techniques and technologies in brain tumor imaging.

Authors:  Benjamin M Ellingson; Martin Bendszus; A Gregory Sorensen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 8.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

9.  Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

Authors:  Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide.

Authors:  Gregory A Christoforidis; Ming Yang; Marinos S Kontzialis; Douglas G Larson; Amir Abduljalil; Michelle Basso; Weilian Yang; Abhik Ray-Chaudhury; Johannes Heverhagen; Michael V Knopp; Rolf F Barth
Journal:  Invest Radiol       Date:  2009-07       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.